JP2010500387A - 結晶形態のエポチロンｂおよび医薬組成物における使用 - Google Patents

結晶形態のエポチロンｂおよび医薬組成物における使用 Download PDF

Info

Publication number
JP2010500387A
JP2010500387A JP2009524113A JP2009524113A JP2010500387A JP 2010500387 A JP2010500387 A JP 2010500387A JP 2009524113 A JP2009524113 A JP 2009524113A JP 2009524113 A JP2009524113 A JP 2009524113A JP 2010500387 A JP2010500387 A JP 2010500387A
Authority
JP
Japan
Prior art keywords
epothilone
crystalline form
treatment
infusion
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009524113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500387A5 (https=
Inventor
エルンスト・キュステルス
ミヒャエル・ムッツ
フランク・シュトヴァッサー
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010500387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2010500387A publication Critical patent/JP2010500387A/ja
Publication of JP2010500387A5 publication Critical patent/JP2010500387A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009524113A 2006-08-16 2007-08-14 結晶形態のエポチロンｂおよび医薬組成物における使用 Pending JP2010500387A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119043 2006-08-16
PCT/EP2007/007173 WO2008019820A2 (en) 2006-08-16 2007-08-14 Crystal form of epothilone b and use in pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2010500387A true JP2010500387A (ja) 2010-01-07
JP2010500387A5 JP2010500387A5 (https=) 2010-09-30

Family

ID=37685905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524113A Pending JP2010500387A (ja) 2006-08-16 2007-08-14 結晶形態のエポチロンｂおよび医薬組成物における使用

Country Status (22)

Country Link
US (1) US8178566B2 (https=)
EP (1) EP2064216A2 (https=)
JP (1) JP2010500387A (https=)
KR (1) KR20090038902A (https=)
CN (1) CN101506217B (https=)
AR (1) AR062375A1 (https=)
AU (1) AU2007286454A1 (https=)
BR (1) BRPI0715963A2 (https=)
CA (1) CA2658475A1 (https=)
CL (1) CL2007002362A1 (https=)
IL (1) IL196558A0 (https=)
MA (1) MA30656B1 (https=)
MX (1) MX2009001635A (https=)
MY (1) MY148355A (https=)
NO (1) NO20091081L (https=)
NZ (1) NZ574194A (https=)
PE (1) PE20081317A1 (https=)
RU (1) RU2009109352A (https=)
TN (1) TN2009000044A1 (https=)
TW (1) TW200815455A (https=)
WO (1) WO2008019820A2 (https=)
ZA (1) ZA200900227B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CN103910742B (zh) * 2013-01-07 2016-07-13 浙江海正药业股份有限公司 一种制备埃博霉素b无定形粉末的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504346A (ja) * 1998-02-19 2002-02-12 ノバルティス アクチエンゲゼルシャフト 細胞増殖抑制剤の発酵生産方法及びそれらの結晶体
JP2004506638A (ja) * 2000-08-16 2004-03-04 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロンアナログの多形
JP2006500031A (ja) * 2002-09-23 2006-01-05 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロンｂの製造、単離および精製方法並びにエポチロンｂのｘ線結晶構造

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287775B6 (sk) 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504346A (ja) * 1998-02-19 2002-02-12 ノバルティス アクチエンゲゼルシャフト 細胞増殖抑制剤の発酵生産方法及びそれらの結晶体
JP2004506638A (ja) * 2000-08-16 2004-03-04 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロンアナログの多形
JP2006500031A (ja) * 2002-09-23 2006-01-05 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロンｂの製造、単離および精製方法並びにエポチロンｂのｘ線結晶構造

Also Published As

Publication number Publication date
KR20090038902A (ko) 2009-04-21
PE20081317A1 (es) 2008-10-28
NO20091081L (no) 2009-03-16
MA30656B1 (fr) 2009-08-03
TN2009000044A1 (en) 2010-08-19
IL196558A0 (en) 2009-11-18
AU2007286454A1 (en) 2008-02-21
CA2658475A1 (en) 2008-02-21
MY148355A (en) 2013-03-29
US8178566B2 (en) 2012-05-15
AR062375A1 (es) 2008-11-05
ZA200900227B (en) 2009-12-30
CL2007002362A1 (es) 2008-08-08
BRPI0715963A2 (pt) 2013-08-06
CN101506217B (zh) 2012-09-05
MX2009001635A (es) 2009-02-23
WO2008019820A2 (en) 2008-02-21
RU2009109352A (ru) 2010-09-27
TW200815455A (en) 2008-04-01
WO2008019820A3 (en) 2008-04-17
US20100160393A1 (en) 2010-06-24
NZ574194A (en) 2011-12-22
CN101506217A (zh) 2009-08-12
EP2064216A2 (en) 2009-06-03

Similar Documents

Publication Publication Date Title
US20070060627A1 (en) Organic compounds
CN101423519A (zh) 粉防己碱有机酸盐及制备方法和应用
RU2358730C2 (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
WO2023016237A1 (zh) 普那布林或其制剂中的杂质及其用途
US20040053978A1 (en) Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
JP2010500387A (ja) 結晶形態のエポチロンｂおよび医薬組成物における使用
JP2025004155A (ja) コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用
US20150238488A1 (en) Drug composition for treating tumors and application thereof
CN107286123A (zh) 一种二苯呋喃类化合物的制备方法与应用
JP2010500387A5 (https=)
KR0155977B1 (ko) 항암조성물
HK40110815A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
CN105037490B (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
BR112021024510B1 (pt) 3-[(2-acetilaminoetiltio)carbonil]propionato de metila isolado, cosmecêutico, nutricosméticos, bebida energética, e, composição farmacêutica
HK40072910A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40072910B (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
CN104619325A (zh) 治疗肿瘤的组合药物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130514